Psychemedics Corporation provides testing services for the detection of drugs of abuse through the analysis of hair samples in the United States and internationally. The company's tests provide quantitative information that can indicate the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period of time. It provides screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, PCP, amphetamines, synthetic cannabinoids, and benzodiazepines, as well as opiates, including heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine. The company offers its services to employers for applicant and employee testing; treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use; and Fortune 500 companies and small to mid-size corporations, as well as school and government entities. Psychemedics Corporation was founded in 1985 and is headquartered in Acton, Massachusetts.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone978-206-8220
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$42.67 million
Profitability
Miscellaneous
Employees250
Next Earnings Date4/23/2019 (Estimated)
OptionableNot Optionable
Psychemedics (NASDAQ:PMD) Frequently Asked Questions
What is Psychemedics' stock symbol?
Psychemedics trades on the NASDAQ under the ticker symbol "PMD."
How often does Psychemedics pay dividends? What is the dividend yield for Psychemedics?
Psychemedics announced a quarterly dividend on Monday, March 4th. Stockholders of record on Thursday, March 14th will be paid a dividend of $0.18 per share on Monday, March 25th. This represents a $0.72 dividend on an annualized basis and a dividend yield of 5.16%. The ex-dividend date of this dividend is Wednesday, March 13th. View Psychemedics' Dividend History.
How were Psychemedics' earnings last quarter?
Psychemedics Corp. (NASDAQ:PMD) issued its quarterly earnings data on Monday, March, 4th. The company reported $0.16 earnings per share for the quarter. The firm earned $9.94 million during the quarter. Psychemedics had a return on equity of 24.55% and a net margin of 10.74%. View Psychemedics' Earnings History.
When is Psychemedics' next earnings date?
Has Psychemedics been receiving favorable news coverage?
Media stories about PMD stock have trended somewhat negative recently, InfoTrie reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Psychemedics earned a coverage optimism score of -1.6 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the next few days.
Who are some of Psychemedics' key competitors?
Some companies that are related to Psychemedics include Celcuity (CELC), Enzo Biochem (ENZ), Fulgent Genetics (FLGT), Miragen Therapeutics (MGEN), PotNetwork (POTN), Biocept (BIOC), First Choice Healthcare Solutions (FCHS), CBA Florida (CBAI), Cancer Genetics (CGIX), OpGen (OPGN), Aeon Global Health (AGHC), Avant Diagnostics (AVDX) and Foundation Medicine (FMI).
What other stocks do shareholders of Psychemedics own?
Who are Psychemedics' key executives?
Psychemedics' management team includes the folowing people:
- Mr. Raymond C. Kubacki Jr., Chairman, CEO & Pres (Age 74)
- Mr. Neil Lerner, VP of Fin. & Treasurer (Age 51)
- Dr. Michael I. Schaffer, VP of Laboratory Operations (Age 74)
- Dr. Werner A. Baumgartner Ph.D., Founder
- Ms. Annette Baumgartner, Founder
Who are Psychemedics' major shareholders?
Psychemedics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Deprince Race & Zollo Inc. (4.98%). Company insiders that own Psychemedics stock include Michael I Schaffer, Neil Lerner and Raymond C Kubacki Jr. View Institutional Ownership Trends for Psychemedics.
Which major investors are selling Psychemedics stock?
PMD stock was sold by a variety of institutional investors in the last quarter, including Deprince Race & Zollo Inc.. Company insiders that have sold Psychemedics company stock in the last year include Michael I Schaffer and Neil Lerner. View Insider Buying and Selling for Psychemedics.
How do I buy shares of Psychemedics?
Shares of PMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Psychemedics' stock price today?
One share of PMD stock can currently be purchased for approximately $13.94.
How big of a company is Psychemedics?
Psychemedics has a market capitalization of $76.77 million and generates $42.67 million in revenue each year. Psychemedics employs 250 workers across the globe.
What is Psychemedics' official website?
How can I contact Psychemedics?
Psychemedics' mailing address is 289 GREAT ROAD, ACTON MA, 01720. The company can be reached via phone at 978-206-8220.
MarketBeat Community Rating for Psychemedics (NASDAQ PMD)
MarketBeat's community ratings are surveys of what our community members think about Psychemedics and other stocks. Vote "Outperform" if you believe PMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
